

ELSEVIER

Prostaglandins & other Lipid Mediators 61 (2000) 425

Author Index

Abe, F., 395 Ataumi, G., 23 Bahouth, S.W., 343 Cantini, C., 117 Capdevila, J.H., 271 Castellani, S., 117 Cherubini, V., 351 Chilton, F.h., 23 Chu, S., 45 Cirino, M., 145 Clay, C.E., 23 Colville-Nash, P.R., 33 Cristofari, C., 117 Denis, D., 145 Dhillon, H., 165 Di Serio, C., 117 Dohi, T., 385 Dussault, I., 1 Edelstein, C., 45 Fain, J.N., 343 Falcioni, G., 351 Falck, J.R., 271, 321 Fiorini, R., 351 Fonteh, A.N., 23 Forman, B.M., 1 Ghosh, S., 45 Gilroy, D.W., 33 Greene, M.E., 45 Hessler, E., 15

Hishinuma, T., 135, 173, 395, 157157 Hitchingham, L., 15 Ishizawa, F., 157157 Junger, H., 335 Kantar, A., 351 Kitayama, S., 385 Kuhn, H., 255 Kulmacz, R.J., 231 Kummerow, F.A., 183 Kurihara, H., 385 La Cava, G., 117 Lai, P.-S., 321 Lee, f., 45 Leffler, C.W., 343 Littarru, G.P., 351 MacDonald, J., 15 Mahfouz, M.M., 183 Masotti, G., 117 Maxey, K.M., 15 McCarville, M.A., 45 McClay, E.F., 75 Metters, K.M., 145 Mizugaki, M., 135, 157, 173, 395 Mizuno, N., 385 Morita, K., 385 Namen, A.M., 23 Nantel, F., 145

Newport, J.A., 45 Northey, A., 145 Nurai, Y., 173 Oberyszyn, T.M., 367 Omata, K., 395 Parrett, M.L., 367 Pitts, J., 45 Rice, A.M., 343 Rivkees, S.A., 343 Ross, M.S., 367 Satoh, J., 173 Shibata, K., 385 Shinohara, H., 385 Sorkin, L.S., 335 Sugiyama, S.I.M., 395 Suzuki, N., 173, 395 Tiano, L., 351 Tong, H., 165 Toyota, T., 173 Tsai, A.-L., 231 Ungar, A., 117 Vallotti, B., 117 Wang, X.S., 45 Wilgus, T.A., 367 Wong, P.Y.-J., 321 Wood, C.E., 165 Yamazaki, T., 135, 157157 Yoshino, H., 385

High, K.P., 23





ELSEVIER

Prostaglandins & other Lipid Mediators 61 (2000) 427-428

Subject Index

Aging kidney, 117 Arachidonic acid, 271 Asthma, 395 Atherosclerosis, 255 Autacoid, 117 Biologic responses, 23 Bovine aorta, 157 Camptothecin analogues, 75 Cancer cells, 23 Ca2+, 385 Catechins, 157 Cerebral ischemia, 165 CPA, 343 Cutaneous inflammation, Cyclooxygenase, 15 Cyclooxygenase-2, 343 Cyclooxygenase inhibitor, 367 Cyclopentenone, 33 Cyclopentenone prostaglandins, 75 Cytochrome P450, 271 Determination, 173 Dexamethasone, 343 Diabetes mellitus, 135, 173 Diabetes type I, 351 Diabetic platelets, 351 14(R), 15(S)-EET epoxyeicosatrienoic acid(14,15-EET) binding,

Endogenous eicosanoid mediator, 15 Endothelial cells, 157 Epigallocatechin gallate, Epoxygenase, 271 Fatty acids, 1, 157 Fetus, 165 Gc/SIM, 135 Gene regulation, 45 Gene transcription, 23 Goblet cell, 145 GPM, 321 Hematopoietic, 45 12-HETE, 385 Hormone, 45 Human platelets, 183 Human skin cancer, 367 Hydroxylase, 271 Inflammation, 255, 335 In situ hybridization, 145 Intestine, 145 Isolated systolic hypertension, 117 Isoproterenol, 343 Iso-prostaglandin, 335 Leukotrienes E₄ (or LTE₄), 395 Ligands, 23 Lipoxygenase, 271 Lysophosphatidylcholine, Malignant cells, 75 Membrane modification, 351

Microdetermination, 395 Molecular enzymology, 255 Monooxygenase, 271 mRNA, 165 Neutrophils, 385 NS-398, 343 Nuclear receptors, 1, 45 Oxidative response, 351 Oxidized low-density lipoprotein, 183 Peroxisome proliferator, 1, 23, 33, 45 Platelet-activating factor, 385 PPAR, 135 PPARy, 23 Pro-inflammatory enzyme, 33 Prostaglandin, 1, 33, 145, Epi-Prostaglandin, 335 Prostaglandin E 2, 343 8-Epi-Prostaglandin F₂, 173 Prostaglandin F-type, 15 Prostaglandin HS-1, 165, Prostaglandin HS-2, 165, 231 Δ ¹²-Prostaglandin J₂, 75 15-deoxy-Δ 12,14Prostaglandin J₂, 15,

Eicosanoids, 255, 335

Prostaglandin J series, 23 Receptors, 145 RT-PCR, 165 Stomach, 145 Structural biology, 255 Thiazolidinediones, 23 Thromboxane, 135, 183, 395 Troglitazone, 135 Tyrosyl radicals, 231 Vascular permeability, 335

